VNDAVanda Pharmaceuticals Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $5.00 · now $5.00 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, VNDA has typically landed between $4.01 and $6.06 — a range of −19.9% to +21.1% from the issuance price $5.00.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,999 overlapping 1 month windows · 2006-09-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.00) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where VNDA has typically landed a month from the 2026-09-16 close of $5 — the range is history, not a prediction.

$4.01worst · -19.9%$6.06best · +21.1%
  • now $5 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.9 (-2.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.5$5.29
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.01$6.06
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,999 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2008-06-26−78.1%−78.1%+0.0%
2008-06-27−75.1%−75.4%+3.7%
2008-07-08−72.3%−73.7%+10.9%
3 best
2009-04-28+1393.9%+0.0%+1393.9%
2009-04-24+1373.4%+0.0%+1373.4%
2009-04-29+1296.0%+0.0%+1349.5%

4,999 overlapping windows · 2006-09-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
45%
−3.2%
n=20
Feb
50%
+0.2%
n=20
Mar
40%
−2.9%
n=20
Apr
45%
−1.1%
n=20
May
45%
+72.2%
n=20
Jun
60%
+4.9%
n=20
Jul
35%
−4.6%
n=20
Aug
45%
−0.2%
n=20
Sep
30%
−5.1%
n=20
Oct
45%
−1.2%
n=20
Nov
65%
+5.4%
n=20
Dec
55%
+5.2%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$10$42026-03-02: 5 insider sales, $2.6M — Polymeropoulos Mihael Hristos, Moran Kevin Patrick, Williams Timothy, Birznieks Gunther …2026-02-23: 1 insider sale, $241K — Honore Tage2025-08: 1 open-market purchase, $42K2026-02: 1 open-market sale, $241K2026-03: 5 open-market sales, $2.6M↑ buys↓ salesdirector Polymeropoulos Mihael Hristos — Sale on 2026-03-02, filed 2 days after the tradeofficer Moran Kevin Patrick — Sale on 2026-03-02, filed 2 days after the tradeofficer Williams Timothy — Sale on 2026-03-02, filed 2 days after the tradeofficer Birznieks Gunther — Sale on 2026-03-02, filed 2 days after the tradeofficer Wijkstrom Joakim — Sale on 2026-03-02, filed 2 days after the tradedirector Honore Tage — Sale on 2026-02-23, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-03-02Polymeropoulos Mihael HristosdirectorSale156,235 @ $8.17$1.3M−5.5% of holding−10.4%−46.3%2,704,496Form 4 · filed 2 days after the trade
2026-03-02Moran Kevin PatrickofficerSale42,442 @ $8.27$351K−9.4% of holding−10.4%−46.3%411,380Form 4 · filed 2 days after the trade
2026-03-02Williams TimothyofficerSale42,434 @ $8.27$351K−10.1% of holding−10.4%−46.3%377,450Form 4 · filed 2 days after the trade
2026-03-02Birznieks GuntherofficerSale42,431 @ $8.27$351K−7.9% of holding−10.4%−46.3%494,197Form 4 · filed 2 days after the trade
2026-03-02Wijkstrom JoakimofficerSale30,800 @ $8.27$255K−8.5% of holding−10.4%−46.3%333,469Form 4 · filed 2 days after the trade
2026-02-23Honore TagedirectorSale30,000 @ $8.03$241K−24.3% of holding−12.3%−47.1%93,469Form 4 · filed 1 day after the trade
2025-08-07Polymeropoulos Mihael HristosdirectorPurchase10,000 @ $4.15$42K+0.4% of holding+5.7%+70.4%2,335,731Form 4 · filed 1 day after the trade
2025-06-13Mitchell Stephen RaydirectorSale7,000 @ $4.59$32K−6.7% of holding+1.8%+23.3%97,082Form 4 · filed 3 days after the trade
2025-05-21Polymeropoulos Mihael HristosdirectorPurchase9,519 @ $4.40$42K+0.4% of holding+0.2%+4.6%2,325,250Form 4 · filed same day
2025-05-21Polymeropoulos Mihael HristosdirectorPurchase481 @ $4.39$2K+0.0% of holding+0.2%+4.6%2,325,731Form 4 · filed same day
2025-05-16Polymeropoulos Mihael HristosdirectorPurchase20,000 @ $4.22$84K+0.9% of holding+7.4%−9.2%2,315,731Form 4 · filed 3 days after the trade
2025-03-06Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $5.02$25K+0.2% of holding−4.2%−19.8%2,290,731Form 4 · filed same day
2025-03-06Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $5.01$25K+0.2% of holding−4.2%−19.8%2,295,731Form 4 · filed same day
2025-03-05Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $5.03$25K+0.2% of holding−7.1%−21.5%2,285,731Form 4 · filed same day
2025-03-05Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $5.01$25K+0.2% of holding−7.1%−21.5%2,280,731Form 4 · filed same day
2025-03-03Polymeropoulos Mihael HristosdirectorPurchase10,000 @ $4.71$47K+0.4% of holding−1.0%−10.5%2,275,731Form 4 · filed 1 day after the trade
2025-02-28Polymeropoulos Mihael HristosdirectorPurchase10,000 @ $4.76$48K+0.4% of holding+2.0%−9.8%2,361,730Form 4 · filed same day
2025-02-27Polymeropoulos Mihael HristosdirectorPurchase10,000 @ $4.76$48K+0.4% of holding+4.5%−11.6%2,351,730Form 4 · filed same day
2025-02-26Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $4.78$24K+0.2% of holding+2.0%−11.3%2,341,730Form 4 · filed same day
2025-02-26Polymeropoulos Mihael HristosdirectorPurchase5,000 @ $4.75$24K+0.2% of holding+2.0%−11.3%2,336,730Form 4 · filed same day
2025-02-25Polymeropoulos Mihael HristosdirectorPurchase10,000 @ $4.46$45K+0.4% of holding+11.0%−4.5%2,331,730Form 4 · filed same day
2025-02-21Moran Kevin PatrickofficerPurchase2,000 @ $4.39$9K+0.6% of holding+12.8%−1.0%355,763Form 4 · filed 3 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

29 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-04Duncan Charles CliffdirectorAward / grant41,60098,701Form 4
2026-06-04McGuire Daniel PatrickofficerAward / grant80,000109,982Form 4
2026-06-04Chrousos PhaedradirectorAward / grant41,600164,950Form 4
2026-06-04Honore TagedirectorAward / grant41,600135,069Form 4
2026-06-04DUGAN RICHARD WdirectorAward / grant41,600219,054Form 4
2026-06-04Mitchell Stephen RaydirectorAward / grant41,600112,846Form 4
2026-06-04Ward Anne SempowskidirectorAward / grant41,600160,667Form 4
2026-05-18Mitchell Stephen RaydirectorGift25,83671,246Form 4
2026-04-22Duncan Charles CliffdirectorAward / grant57,10157,101Form 4
2026-02-18Wijkstrom JoakimofficerAward / grant125,000364,269Form 4
2026-02-18Birznieks GuntherofficerAward / grant125,000536,628Form 4
2026-02-18Williams TimothyofficerAward / grant125,000419,884Form 4
2026-02-18Moran Kevin PatrickofficerAward / grant125,000453,822Form 4
2026-02-18Polymeropoulos Mihael HristosdirectorAward / grant525,0002,860,731Form 4
2025-06-05Chrousos PhaedradirectorAward / grant59,225123,350Form 4
2025-06-05Ward Anne SempowskidirectorAward / grant59,225119,067Form 4
2025-06-05DUGAN RICHARD WdirectorAward / grant59,225177,454Form 4
2025-06-05Mitchell Stephen RaydirectorAward / grant59,225104,082Form 4
2025-06-05Honore TagedirectorAward / grant59,225123,469Form 4
2025-03-01Polymeropoulos Mihael HristosdirectorWithheld for tax95,9992,265,731Form 4
2025-03-01Moran Kevin PatrickofficerWithheld for tax26,941328,822Form 4
2025-03-01Williams TimothyofficerWithheld for tax26,941294,884Form 4
2025-03-01Birznieks GuntherofficerWithheld for tax26,941411,628Form 4
2025-03-01Wijkstrom JoakimofficerWithheld for tax15,520239,269Form 4
2025-02-18Williams TimothyofficerAward / grant125,000321,825Form 4
2025-02-18Birznieks GuntherofficerAward / grant125,000438,569Form 4
2025-02-18Moran Kevin PatrickofficerAward / grant125,000353,763Form 4
2025-02-18Wijkstrom JoakimofficerAward / grant125,000254,789Form 4
2025-02-18Polymeropoulos Mihael HristosdirectorAward / grant450,0002,321,730Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.